All Issue

2026 Vol.56, Issue 2

Review Article

Therapeutic Insights on Iclaprim: A Review of Mechanism, Efficacy and Safety in Treatment
Shohana Ferdoush1
,
Mohammad Saydur Rahman1*
,
Jannatul Mawa Mim1
,
Safaet Jamil Sifat1
,
Md. Robin Mia1
,
Md. Ashrarul Hasib1
,
Abdullah Al Mamun1
,
Bitop Halder1
,
Young-Sang Koh23*
1Department of Pharmacy, Jagannath University, Dhaka-1100, Bangladesh
2Department of Microbiology and Immunology, College of Medicine, Jeju National University, Jeju 63243, Republic of Korea
3Jeju Research Center for Natural Medicine, Core Research Institute, Jeju National University, Jeju 63243, Republic of Korea
*saydur_pr@yahoo.com,saydur_pr@pharm.jnu.ac.bd
*yskoh7@jejunu.ac.kr
10 August 2026. pp. 73-83
PDF XML Citation
Abstract

The ongoing problem of antibiotic resistance is widely recognized as a contributing factor to the decline in community health. Several novel dihydrofolate reductase (DHFR) inhibitors have recently advanced into clinical development because of their potent anticancer and antibacterial activities. To combat bacterial infections, DHFR inhibitors such as trimethoprim are often used in combination with sulfonamide. Iclaprim is an inhibitor of bacterial DHFR, interferes with thymidine synthesis and is primarily metabolized by the enzymes CYP3A4 and CYP2C19. This review aimed to investigate the pharmacological progression of its efficacy, tolerability, microbiology, and in vitro susceptibility in the treatment of serious skin infections and nosocomial pneumonia. Related articles were searched from 1995 to 2023 using specific keywords in PubMed and Google Scholar, with articles excluded based on some criteria such as including antibiotics, iclaprim etc and excluding duplicate articles, editorials, commentaries, letters to the editor etc. The discussion presents the pharmacological studies based on experimental findings and provides an overview of three phases of clinical trial. However, several crucial parameters still require further research and development. In addition, selected in vitro results are presented. Clinical trials investigating hospital-associated iclaprim for pneumonia are currently underway. Currently, iclaprim, an antimicrobial agent against Gram-positive organisms, has shown potential in the treatment of skin infections. However, further studies are needed to clarify its potential role in clinical practice.

Keywords
Antibiotics
Dihydrofolate reductase inhibitors
Iclaprim
Nosocomial pneumonia
References
1

Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol. 2006;71(7):941-948.

10.1016/j.bcp.2005.10.052
2

Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975;64(5):365-370.

3

Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72-80.

10.1016/j.mib.2019.10.008
4

Libecco JA, Powell KR. Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev. 2004;25(11):375-380.

10.1542/pir.25.11.375
5

Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16): 851-1858.

10.1503/cmaj.11115221989472PMC3216436
6

Huang DB, Dryden M. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. Future Microbiol. 2018;13(9):957-969.

10.2217/fmb-2018-0061
7

Wang L, Fan J, Zheng L, Chen L. Efficacy and safety of iclaprim for the treatment of skin structures and soft tissue infections: a methodological framework. Front Pharmacol. 2022;13:932688.

10.3389/fphar.2022.93268835928265PMC9344044
8

Cairns EA, Benson MJ, Bedoya-Pérez MA, Macphail SL, Mohan A, Cohen R, et al. Medicinal cannabis for psychiatry- elated conditions: an overview of current Australian prescribing. Front Pharmacol. 2023;14:1142680.

10.3389/fphar.2023.114268037346297PMC10279775
9

Noviello S, Hawser S, Sader H, Huang DB. In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016. J Glob Antimicrob Resist. 2019; 6:236-238.

10.1016/j.jgar.2018.10.018
10

Laue H, Valensise T, Seguin A, Hawser S, Lociuro S, Islam K. Effect of human plasma on the antimicrobial activity of iclaprim in vitro. J Antimicrob Chemother. 2007;60(6):1388-1390.

10.1093/jac/dkm392
11

Hao L, Zhou J, Yang H, He C, Shu W, Song H, et al. Anti-virulence potential of iclaprim, a novel folic acid synthesis inhibitor, against Staphylococcus aureus. Appl Microbiol Biotechnol. 2024;108(1):432.

10.1007/s00253-024-13268-239102054PMC11300511
12

Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362-386.

10.1128/CMR.05022-1122491776PMC3346297
13

Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett. 2003;13(23):4217-4221.

10.1016/j.bmcl.2003.07.023
14

Sorbera LA, Castaner J, Rabasseda X. Iclaprim: antibacterial dihydrofolate reductase inhibitor. Drugs Future. 2004; 9(3):220-225.

10.1358/dof.2004.029.03.785046
15

Peppard WJ, Johnston CJ, Urmanski AM. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. Expert Rev Anti Infect Ther. 2008;6(1):83-99.

10.1586/14787210.6.1.83
16

Rodriguez-Bano J, Alcala J, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Escherichia coli producing SHV-type extended-spectrum β-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother. 2009;63(4):781-784.

10.1093/jac/dkp028
17

Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs. 2007;16(9):1441-1448.

10.1517/13543784.16.9.1441
18

Reeve SM, Si D, Krucinska J, Yan Y, Viswanathan K, Wang S, et al. Toward broad spectrum dihydrofolate reductase inhibitors targeting trimethoprim resistant enzymes identified in clinical isolates of methicillin resistant Staphylococcus aureus. ACS Infect Dis. 2019;5(11):1896-1906.

10.1021/acsinfecdis.9b0022231565920PMC7025792
19

Oefner C, Bandera M, Haldimann A, Laue H, Schulz H, Mukhija S, et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother. 2009;63(4):687-698.

10.1093/jac/dkp024
20

Huang DB, Strader CD, MacDonald JS, VanArendonk M, Peck R, Holland T. An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by Gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018;5(2):ofy003.

10.1093/ofid/ofy00329423421PMC5798018
21

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361-369.

10.1016/S0140-6736(19)33220-9
22

Huang DB, O’Riordan W, Overcash JS, Heller B, Amin F, File TM, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens: REVIVE-1. Clin Infect Dis. 2018;66(8):1222-1229.

10.1093/cid/cix987
23

Holland TL, O’Riordan W, McManus A, Shin E, Borghei A, File TM Jr, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother. 2018;62(5):e02580-17.

10.1128/AAC.02580-1729530858PMC5923167
24

Huang DB, Corey GR, Holland TL, Lodise T, O’Riordan W, Wilcox MH, et al. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2018;52(2):233-240.

10.1016/j.ijantimicag.2018.05.012
25

Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, et al. A Phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to gram-positive pathogens. Clin Ther. 2017;39(8):1706-1718.

10.1016/j.clinthera.2017.07.007
26

Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009;53(7): 834-2840.

10.1128/AAC.01383-0819414572PMC2704699
27

Andrews J, Honeybourne D, Ashby J, Jevons G, Fraise A, Fry P, et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother. 2007;60(3):677-680.

10.1093/jac/dkm242
28

Park JH, Craig W, Marchillo K, Huang DB, Andes DR. Identification of the in vivo pharmacokinetics and pharmacodynamic driver of iclaprim. Antimicrob Agents Chemother. 2018;62(4):e02550-17.

10.1128/AAC.02550-1729378717PMC5913961
29

Huang DB. A pharmacokinetic and pharmacodynamic evaluation of iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse abscess model. J Med Microbiol. 2019;8(1):77-80.

10.1099/jmm.0.000878
30

Wróbel A, Arciszewska K, Maliszewski D, Drozdowska D. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors. J Antibiot (Tokyo). 2020;73(1):5-27.

10.1038/s41429-019-0240-631578455PMC7102388
31

Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs. 2008;9(2):210-225.

32

Morgan A, Cofer C, Stevens DL. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. Future Microbiol. 2009;4(2):131-144.

10.2217/17460913.4.2.131
33

Giacobbe DR, Labate L, Vena A, Bassetti M. Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis. 2021;34(2):109-117.

10.1097/QCO.0000000000000708
34

Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis. 2019;68(Suppl 3): 206-S212.

10.1093/cid/ciz00430957166PMC6451992
35

Barton E, MacGowan A. Future treatment options for Gram-positive infections—looking ahead. Clin Microbiol Infect. 2009;15:17-25.

10.1111/j.1469-0691.2009.03055.x
36

Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017;4(2):49-73.

10.1177/204993611769050128634536PMC5467880
37

Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A. New variant of CTX-M-type extended-spectrum β-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. Antimicrob Agents Chemother. 2009;53(10):4518-4521.

10.1128/AAC.00461-0919620330PMC2764165
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 56
  • No :2
  • Pages :73-83
  • Received Date : 2026-01-05
  • Revised Date : 2026-06-22
  • Accepted Date : 2026-06-30
  • DOI :https://doi.org/10.4167/jbv.2026.56.2.073
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close